A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer (ARC-9)
|Arcus Biosciences, Inc.
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / email@example.com
The purpose of this study is to help understand whether an investigational drug, AB928 (referred to as etrumadenant and etruma), is safe and effective when given in combination with other therapies to patients with metastatic colorectal cancer (mCRC). Etruma may be combined with other investigational drugs, known as AB680 and zimberelimab (AB122), or maybe combined with drugs that are approved by the United States Food and Drug Administration (U.S. FDA) and other government agencies to treat mCRC.
This study is closed
Gulam Manji, MD, PhD
|Are you at least 18 years old?
|Do you have metastatic colorectal adenocarcinoma (colon cancer)?
|Is your life expectancy longer than 3 months?
|Are you able to take oral medications?